Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) — Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that clinical data from the ongoing IMR-687 Phase 2a open label extension (OLE) clinical trial in adult patients with sickle cell disease (SCD) will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020.

The presentation (abstract #1726), titled “Benefits and Safety of Long-Term Use of IMR-687 as Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients,” is currently available on the ASH website. The pre-recorded data presentation will be given by Lanetta Bronte-Hall, M.D., M.P.H., M.S.P.H., President and Chief Executive Officer of the Foundation for Sickle Cell Disease Research and will be available for on-demand viewing on Sunday, December 6, 2020 from 7:00 a.m. to 3:30 p.m.PT.

Imara completed dosing patients in the IMR-687 Phase 2a clinical trial in patients with SCD during the third quarter of 2020 and plans to report top-line data late in the fourth quarter of 2020. Imara also expects to report additional data from approximately 10 to 15 patients in the OLE clinical trial in the first quarter of 2021.

About IMR-687

IMR-687 is a highly selective and potent small molecule inhibitor of PDE9. PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule that plays a role in vascular biology. Lower levels of cGMP are found in people with SCD and beta-thalassemia and are associated with reduced blood flow, increased inflammation, greater cell adhesion and reduced nitric oxide mediated vasodilation.

Blocking PDE9 acts to increase cGMP levels, which is associated with reactivation of fetal hemoglobin (HbF), a natural hemoglobin produced during fetal development. Increased levels of HbF in RBCs have been demonstrated to improve symptomology and substantially lower disease burden in both patients with SCD and patients with beta-thalassemia.

About Imara

Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the content of, and timing with respect to, reporting of data from the Phase 2a and OLE clinical trials evaluating IMR-687 in patients with sickle cell disease. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the impact of extraordinary external events, such as the risks and uncertainties resulting from the impact of the COVID-19 pandemic on the Company’s business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities and ability to conduct and readout data from its ongoing Phase 2a and OLE clinical trials of IMR-687 in sickle cell disease and other factors discussed in the “Risk Factors” section of the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:

Gina Nugent
Ten Bridge Communications
617-460-3579
[email protected]

Investor Contact:

Michael Gray
617-835-4061
[email protected]



Plug Power and Gaussin Collaborate on Hydrogen-Powered Transportation Vehicles

Goal to Decarbonize the Logistics Ecosystem with Green Hydrogen Fuel

LATHAM, N.Y., Nov. 30, 2020 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ:PLUG), a leading provider of hydrogen engines and fueling solutions enabling e-mobility, are collaborating to bring a commercial suite of ProGen-powered Gaussin transportation vehicles to market in 2021 as a solution to decarbonize the logistics ecosystem. Integrated solutions, ranging from ProGen-powered Gaussin terminal tractors to automated guided vehicles, will use green hydrogen produced by Plug Power’s best of class PEM electrolyzer solution.

Gaussin is a pioneer in hydrogen-powered heavy duty vehicles and brings over two decades of experience deploying emission-free vehicles across Europe, Middle East and Asia for logistic centers, seaports and airports. Through the integration with Plug Power’s industry-leading ProGen hydrogen engines, Gaussin further positions itself as a key OEM in the emerging hydrogen economy. Plug Power and Gaussin will target new cargo markets, including logistic centers, seaports and airports in Europe, the United States, and globally beyond. The first vehicles are expected to be available commercially in early-2021.

Plug Power is the leading provider of hydrogen fuel cell engines and largest user of liquid hydrogen globally. The Company provides hydrogen and fuel cell solutions for e-mobility applications, providing a range of 30 to 125 kW fuel cells for heavy-duty fleet and on-road vehicle applications. Plug Power’s modular ProGen fuel cell engines range from 30kW to 125kW, and designed for OEMs like Gaussin to integrate into zero-emission vehicles. The company is executing on a strategy to accelerate its PEM electrolyzer business in the US and Europe, leveraging distribution channels and developing a multi-megawatt scalable network for green hydrogen production.

“Our partnerships with OEM leaders, like Gaussin, allow us to drive green hydrogen solutions in the United States, Europe and beyond,” said Andy Marsh, CEO for Plug Power. “We are working to integrate ProGen engines in cargo transportation and on-road vehicle applications with best-in-class partners to make the freight and logistics markets greener with our green hydrogen and sustainable energy solutions.”

“Gaussin values its partnership with Plug Power as we further penetrate the sustainable cargo transportation vehicle market,” said Christophe Gaussin, CEO for Gaussin. “Hydrogen is a critical global fuel solution, and Gaussin intended to be a leading solutions provider for the zero-emission vehicle space.”

The transportation sector is known as one of the largest fuel consumers of the global energy market. Hydrogen is an attractive fuel, specifically being promoted in Europe where diesel bans are mandated for large cities starting in 2024. As highlighted in the European Commission’s Hydrogen Industrial Strategy, hydrogen energy is “a pillar” to the European Union’s growth and global competitiveness. Hydrogen also takes a prominent role in the European Green Deal for making Europe the world’s first climate-neutral continent by 2050. According to McKinsey & Company, the global hydrogen economy could reach $2.5 trillion by 2050. Hydrogen is ideal for this industry as a clean, cost effective and energy-dense (3x gasoline or diesel) fuel.

About Plug Power

Plug Power is building the hydrogen economy as the leading provider of comprehensive hydrogen fuel cell (HFC) turnkey solutions. The Company’s innovative technology powers electric motors with hydrogen fuel cells amid an ongoing paradigm shift in the power, energy, and transportation industries to address climate change and energy security, while providing efficiency gains and meeting sustainability goals.

Plug Power created the first commercially viable market for hydrogen fuel cell (HFC) technology. As a result, the Company has deployed over 38,000 fuel cell systems for e-mobility, more than anyone else in the world, and has become the largest buyer of liquid hydrogen, having built and operated a hydrogen highway across North America. Plug Power delivers a significant value proposition to end-customers, including meaningful environmental benefits, efficiency gains, fast fueling, and lower operational costs.

Plug Power’s vertically-integrated GenKey solution ties together all critical elements to power, fuel, and provide service to customers such as Amazon, BMW, The Southern Company, Carrefour, and Walmart. The Company is now leveraging its know-how, modular product architecture and foundational customers to rapidly expand into other key markets including zero-emission on-road vehicles, robotics, and data centers.

About Gaussin

Gaussin is an engineering company that designs, assembles and sells innovative products and services in the transport and logistics field. Its know-how encompasses cargo and passenger transport, autonomous technologies allowing for self driving solutions such as Automotive Guided Vehicle, and the integration of all types of batteries, particularly electric and hydrogen fuel cells. With more than 50,000 vehicles worldwide, Gaussin enjoys a strong reputation in four fast expanding markets: port terminals, airports, logistics and people mobility. The group has formed strategic partnerships with major global players in order to accelerate its market penetration: Siemens Logistics in the airport field, Bolloré Ports and ST Engineering in ports, UPS in logistics and Bluebus for people mobility. Gaussin has extended its business model with licensing agreements that are aimed at speeding up the use of its technology throughout the world. The purchase of Metalliance has resulted in the emergence of a group with over 200 employees and €50M turnover.

In October 2019, the Group won the World Challenge for Self-Driving Transport in the Leading Company Category, Best Energy and Environmental Sustainability. Gaussin has been listed on Euronext Growth in Paris since 2010 (EURONEXT GROWTH – FR0013495298).

More information on www.gaussin.com.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Plug Power Inc. (“PLUG”), including but not limited to statements about PLUG’s expectations regarding the capital raise positioning PLUG to execute and accelerate on its green hydrogen strategy as well as other strategic growth initiatives, expectations regarding the timing of the operations of PLUG’s hydrogen plants and the size of the use and demand for liquid hydrogen, PLUG’s ability to work with strategic partners to source low-cost renewable power and drive down the cost of renewable power and green hydrogen, and expectations regarding PLUG’s technology facilitating the rapid growth of the hydrogen economy. You are cautioned that such statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times that, or by which, such performance or results will have been achieved. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of PLUG in general, see PLUG’s public filings with the Securities and Exchange Commission, including the “Risk Factors” section of PLUG’s Annual Report on Form 10-K for the year ended December 31, 2019 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made as of the date hereof, and PLUG undertakes no obligation to update such statements as a result of new information.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6921d2d1-7652-4adb-bd2a-1fc83643dd3e

Media Contact

Ian Martorana
The Bulleit Group
(415) 237-3681
[email protected] 



Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine

– Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity

– AUTO6NG builds on this approach utilizing the same GD2 CAR alongside additional programming modules to enhance the efficacy and persistence, expected to enter the clinic in 2021

LONDON, Nov. 30, 2020 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces publication of AUTO6 (1RG-CAR T) Phase 1 data in Science Translational Medicine. AUTO6 is a second generation GD2-targeting CAR T candidate, developed in collaboration with UCL, and the trial was sponsored and run by Cancer Research UK’s Centre for Drug Development.

These new results highlight that AUTO6 can induce rapid regression of bulky disease in a solid tumor setting without inducing on-target off-tumor toxicity, despite dose dependent CAR T expansion. CAR T cell expansion was observed in all six patients treated at the higher cell dose cohorts in this Phase 1 study. Three of these six patients demonstrated evidence of transient CAR T cell activity, including cytokine release syndrome, and regression of soft tissue and bone marrow disease activity. The GD2 binder used in AUTO6 has been designed to minimize on-target off-tumor neurotoxicity associated with GD2 expression at low levels in pain fibers and the brain. Despite the presence of clear CAR T cell activity, no neurotoxicity was observed. The publication also suggests that, whilst AUTO6 is a valid and safe strategy for targeting neuroblastoma, further modifications are required to promote CAR T cell persistence and induce deeper and more durable responses for these patients.

“We are encouraged by the anti-tumor activity in neuroblastoma, a disease where there are limited therapeutic options for children with relapsed or refractory disease,” said Dr Karin Straathof, Consultant Paediatric Oncologist and research group leader at UCL Great Ormond Street Institute for Child Health. “This is of particular importance as this activity was observed in the absence of neurotoxicity which occurs with antibody-based approaches that target GD2.”

Nigel Blackburn, director of drug development at Cancer Research UK, said, “Children who have hard to treat, or relapsed cancer have limited treatment options open to them, and early results of AUTO6 are encouraging. We look forward to seeing the next steps in the development of AUTO6NG, and if the treatment has durable effects in neuroblastoma.”

“This is amongst the clearest data which demonstrate that CAR T cells can be highly active against advanced solid cancers,” said Dr Martin Pule, CSO and founder of Autolus and director of the UCL CAR T programme. “It is encouraging that highly active CAR T cells do not cause on-target off-tumor neurotoxicity and the findings represent an important step in our ongoing efforts to develop CAR T cell therapies for solid cancers.”

These data support Autolus’ continued development of AUTO6NG, which builds on this approach utilizing the same GD2 CAR alongside additional programming modules designed to enhance efficacy and persistence. Earlier this year at the American Association for Cancer Research (AACR) meeting, Autolus announced a preclinical data update demonstrating the validity of GD2 as a CAR T target in small cell lung cancer (SCLC) and the ability of Autolus’ efficacy-enhancing modules to drive in vivo efficacy in an SCLC mouse model. The data also suggested AUTO6NG can overcome the immune suppressive mechanisms in the tumor microenvironment. Autolus plans to test AUTO6NG in a Phase 1 study in 2021.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defence mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. For more information please visit www.autolus.com.

About UCL Business PLC
UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market. For further information, please visit: www.uclb.com Twitter: @UCL_Business

About Cancer Research UK

  • Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 40 years.
  • Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK’s ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK’s vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK’s work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org. Follow us on Twitter and Facebook.

About
N
euroblastoma
Neuroblastoma is the most common solid tumor in children that occurs outside of the brain and makes up 8% of the total number of children’s cancers. The site of origin is either in one of the two adrenal glands situated in the abdomen or in nerve tissue that runs alongside the spinal cord, in the neck, chest, abdomen or pelvis. The adrenal glands normally release hormones to maintain blood pressure and enable the body to respond to stress. In up to half of patients diagnosed with neuroblastoma, the tumor has spread to tissues beyond the original site such as the bone marrow, bone, lymph nodes, liver, and skin. As with most cancers, the cause of neuroblastoma is not known. When the lesion is localised, it is generally curable. However, long-term survival for children with advanced disease older than 18 months of age is poor despite aggressive multimodal therapy.

About AUTO6NG
AUTO6NG is a next generation programmed T cell product candidate in pre-clinical development.  AUTO6NG builds on preliminary proof of concept data from AUTO6, a CAR targeting GD2-expression cancer cell currently in clinical development for the treatment of neuroblastoma. AUTO6NG incorporates additional cell programming modules to overcome immune suppressive defence mechanisms in the tumor microenvironment, in addition to endowing the CAR T cells with extended persistence capacity. AUTO6NG is currently in preclinical development for the potential treatment of both neuroblastoma and other GD2-expressing solid tumors, including osteosarcoma, soft tissue sarcoma, small cell lung cancer, and melanoma.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding Autolus’ financial condition and results of operations, including its expected cash runway; the development of Autolus’ product candidates, including statements regarding the timing of initiation, completion and the outcome of pre-clinical studies or clinical trials and related preparatory work, and the periods during which the results of the studies and trials will become available; Autolus’ plans to research, develop, manufacture and commercialize its product candidates; the potential for Autolus’ product candidates to be alternatives in the therapeutic areas investigated; and Autolus’ manufacturing capabilities and strategy. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Autolus’ Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 3, 2020 as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ future filings with the Securities and Exchange Commission from time to time. All information in this press release is as of the date of the release, and the company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Contact:

Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
[email protected]

Julia Wilson
+44 (0) 7818 430877
[email protected]

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
[email protected]



Enthusiast Gaming Amends and Expands its Credit Facilities to Support its Growth Strategy  

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV), the largest gaming platform in North America, reaching over 300 million monthly video game and esports fans worldwide, today announced that it has entered into an amended and restated letter agreement (the “Amended Credit Agreement”) with the Company’s lender, resulting in an increase in the total size of its credit facilities, under more flexible and growth-friendly terms.

The Amended Credit Agreement increases the Company’s total borrowing capacity to up to $24 million, including a term loan in the amount of $10 million, and revolving demand loans of up to $14 million. The move to revolving facilities will provide the Company the ability to utilize cash-on-hand to reduce interest costs.

“This positive development for our balance sheet complements our capital plan as we continue to press on and focus on our strategic growth priorities”,
said Adrian Montgomery, CEO of Enthusiast Gaming.
“The modest increase in our borrowing base provides great options, while complementing our anticipated Nasdaq listing and entry into the U.S. capital markets.”

Amounts drawn under the Amended Credit Agreement are to be used for (i) refinancing of obligations under the pre-existing letter agreement with the Lender dated August 2, 2019, as amended on September 30, 2019 and August 31, 2020 (ii) working capital purposes and (iii) financing of future acquisitions.

Other material terms of the Amended Credit Facility, including the term and rate of interest, remain unchanged.

About Enthusiast Gaming

Enthusiast Gaming (TSX: EGLX)(OTCQB: ENGMF)(FSE: 2AV) is building the world’s largest social network of communities for video game and Esports fans that reaches over 300 million gaming enthusiasts on a monthly basis. Already the largest gaming platform in North America and the United Kingdom, the Company’s business is comprised of four main pillars: Esports, Content, Talent and Entertainment. Enthusiast Gaming’s esports division, Luminosity Gaming, is a leading global esports franchise that consists of 7 professional esports teams under ownership and management, including the Vancouver Titans Overwatch team and the Seattle Surge Call of Duty team. Enthusiast’s gaming content division includes 2 of the top 20 gaming media and entertainment video brands with BCC Gaming and Arcade Cloud, reaching more than 50MM unique viewers a month across 9 YouTube channels, 8 Snapchat shows and related Facebook, Instagram and TikTok accounts. Its 100 gaming-related websites including The Sims Resource, Destructoid, and The Escapist collectively generate 1.1 billion page views monthly. Enthusiast’s talent division works with nearly 1,000 YouTube creators generating nearly 3 billion views a month working with leading gamer talent such as Pokimane, Flamingo, Anomaly, and The Sidemen. Enthusiast’s entertainment business includes Canada’s largest gaming expo, EGLX (eglx.com), and the largest mobile gaming event in Europe, Pocket Gamer Connects (pgconnects.com). For more information on the Company visit enthusiastgaming.com. For more information on Luminosity Gaming visit luminosity.gg.

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that Enthusiast anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. Forward-looking statements in this news release include, but are not limited to statements relating to the Enthusiast Gaming’s filing of a listing application with NASDAQ and its plans to file a Form 40-F with the SEC and any regulatory or other approvals required in connection therewith as well as the diversification of Enthusiast Gaming’s shareholder base, increased liquidity for shareholders and the acceleration of its business strategy.

Forward-looking statements are based on assumptions, including expectations and assumptions concerning: interest and foreign exchange rates; capital efficiencies, cost saving and synergies; growth and growth rates; the success in the esports and media industry; and the anticipated benefits of listing on the NASDAQ and the Company’s growth plan. While Enthusiast Gaming considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. In addition, forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks related risks associated with general economic conditions; adverse industry events; future legislative, tax and regulatory developments. Readers are cautioned that the foregoing list is not exhaustive and other risks set out in Enthusiast Gaming public disclosure recorded filed under the Company’s provide on www.sedar.com, including those contained in the prospectus. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. For more information on the risk, uncertainties and assumptions that could cause anticipated opportunities and actual results to differ materially, please refer to the public filings of Enthusiast Gaming which are available on SEDAR at www.sedar.com. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Enthusiast Gaming disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 



For further information: Enthusiast Gaming Contact: Alex Macdonald, CFO, 416.623.9360

Investor Relations Contact: 
Eric Bernofsky, Chief Corporate Officer, 416.623.9360
[email protected]

Media Relations – ID Public Relations
[email protected]

Silver Bull Announces Independent Proxy Advisory Firms ISS and Glass Lewis Recommendations “FOR” Both Proposals at Upcoming Special Meeting of Shareholders

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) — Silver Bull Resources, Inc. (TSX: SVB, OTCQB: SVBL) (“SilverBull” or the “Company”) is pleased to report that, in respect of its upcoming special meeting of shareholders, both Institutional Shareholder Services (“ISS”) and Glass, Lewis & Co. (“Glass Lewis”), the leading independent proxy advisor firms who provide voting recommendations to institutional investors, have recommended that the Company’s shareholders vote FOR the proposals to increase the number of authorized shares of Silver Bull common stock and to change the Company’s name to MaxMetals Corp. (collectively, the “proposals”).

In their recommendations to shareholders on voting FOR the increase in the number of authorized shares, both ISS and Glass Lewis agreed with the Company’s board of directors on the need for additional shares to enable the Company to raise additional capital for furthering the development of the Sierra Mojada Project in Mexico and the Beskauga property in Kazakhstan. Glass Lewis further noted that “it would be in shareholders’ best interest to provide the board with flexibility to obtain additional capital—including through participation in private placement transactions—going forward.”


Authorized Share Increase Proposal

By increasing the number of authorized shares of Silver Bull common stock now, the Company will be able to act in a timely manner when the need to raise equity capital arises or when the Company’s board of directors believes it is in the best interests of the Company and shareholders to take action, without the delay and expense that would be required at that time to obtain shareholder approval to increase the authorized shares. Business purposes for which the Company could seek to raise additional capital including furthering the development of the Sierra Mojada project in Mexico and the Beskauga property (and other properties) located in Kazakhstan. Virtually all junior exploration companies like the Company remain as viable companies and conduct their mineral exploration activities by raising funds by issuing shares from time to time. In the absence of an affirmative vote to increase the number of authorized shares of Silver Bull common stock, the Company will have an insufficient number of authorized shares to raise funds to fund general corporate overhead or cover the costs associated with maintaining its interests in the Sierra Mojada project in Mexico or its potential mineral interests in Kazakhstan.


Name Change Proposal

The Company’s board of directors believes that the proposed name change from Silver Bull Resources, Inc. to MaxMetals Corp. is appropriate to better describe the Company’s focus and anticipated exploration activities.


Silver Bull Special Meeting of Shareholders

The special meeting of shareholders of Silver Bull is scheduled for 10:00 a.m. PT on Wednesday, December 16, 2020, at the Company’s offices at 777 Dunsmuir Street, Suite 1610, Vancouver, British Columbia.

Additional information concerning the proposals can be found in the definitive proxy statement dated November 6, 2020. An electronic copy of the definitive proxy statement is available on the Company’s website at www.silverbullresources.com, on the Company’s EDGAR profile at www.sec.gov, and on its SEDAR profile at www.sedar.com.


How to Vote Your Shares

  • By Internet: If you received a Notice of Internet Availability of Proxy Materials (the “Notice”), you can access the Company’s proxy materials and vote online at www.proxyvote.com. Further instructions to vote online are provided in the Notice.
     
  • By Telephone: You may vote your shares by calling 1-800-690-6903. You will need to follow the instructions on your proxy card and the voice prompts.

Due to the essence of time, shareholders are encouraged to vote by Internet or telephone as set out above.


Shareholder Questions and Assistance

Silver Bull shareholders who require assistance with voting their shares can contact the Company’s proxy solicitation agent, Laurel Hill Advisory Group:

Laurel Hill Advisory Group  
North America Toll-Free: 1-877-452-7184 
Collect Call Outside North America: 1-416-304-0211 
Email:
[email protected]


Important Information

This communication may be deemed to be solicitation material in connection with the proposals to be considered at the Company’s upcoming special meeting of shareholders. In connection with the proposals, Silver Bull filed a definitive proxy statement on Schedule 14A with the U.S. Securities and Exchange Commission (the “SEC”) on November 6, 2020. Shareholders are urged to read the definitive proxy statement and all other relevant documents filed with the SEC because they contain important information about the proposals. An electronic copy of the definitive proxy statement is available on the Company’s website at www.silverbullresources.com, on the Company’s EDGAR profile at www.sec.gov, and on its SEDAR profile at www.sedar.com.


Participants in the Solicitation

Silver Bull and its directors and executive officers may be deemed to be participants in the solicitation of proxies from Silver Bull shareholders in respect of the proposals to be considered at the Company’s upcoming special meeting of shareholders. Information about the directors and executive officers of Silver Bull can be found in its Annual Report on Form 10-K for the year ended October 31, 2019 filed with the SEC on January 13, 2020, filings on Form 3, 4 and 5 filed with the SEC, and the Company’s definitive proxy statement for the upcoming special meeting of shareholders filed with the SEC on November 6, 2020.


About Silver Bull

Silver Bull is a Vancouver-based mineral exploration company whose shares are listed on the TSX and trade on the OTCQB in the United States. Silver Bull recently signed an Option Agreement to acquire the Beskauga Copper-Gold Project, located in North Eastern Kazakhstan. This agreement is subject to on the ground due diligence, which is now underway, and is expected to be completed on or before January 15, 2021. In addition, Silver Bull owns the Sierra Mojada Project which is located 150 kilometers north of the city of Torreon in Coahuila, Mexico, and is highly prospective for silver and zinc. Sierra Mojada is currently under a joint venture option with South32 International Investment Holdings Pty Ltd.

On behalf of the Board of Directors
“Tim Barry”

Tim Barry, CPAusIMM

Chief Executive Officer, President and Director

INVESTOR RELATIONS:

+1 604 687 5800
[email protected]


Cautionary note regarding forward looking statements:
Certain statements in this news release are “forward-looking” within the meaning of applicable securities legislation. Forward-looking statements can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. Forward-looking statements include, but are not limited to, statements relating to the proposals to be considered at the upcoming special meeting of shareholders and the completion of due diligence in respect of the Beskauga Option Agreement. Forward-looking statements are necessarily based upon the current belief, opinions and expectations of management that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and other contingencies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements. These factors include, among others, market prices, metal prices, availability of capital and financing, general economic, market or business conditions, as well as other risk factors set out under the heading “Risk Factors” in the Annual Report on Form 10-K for the year ended October 31, 2019, which is available on SEDAR at www.sedar.com. Investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

 



IGM Biosciences to Host Conference Call and Webcast to Review IGM-2323 Data Presented at the 62nd Annual ASH Meeting

MOUNTAIN VIEW, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast on Saturday, December 5, 2020, at 2:00 p.m. ET. The event will take place following a poster presentation featuring the first clinical data from the Company’s Phase 1 trial evaluating IGM-2323 at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

The conference call may be accessed by dialing (866) 649-1996 (domestic) or (409) 217-8769 (international) and referring to conference ID 1141638. A live webcast of the presentation will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

About IGM Biosciences, Inc.

Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing and protein engineering hurdles that have limited the therapeutic use of IgM antibodies. Through its efforts, IGM Biosciences has created a proprietary IgM technology platform for the development of IgM antibodies for those clinical indications where their inherent properties may provide advantages as compared to IgG antibodies.

Contact:

Argot Partners
David Pitts
212-600-1902
[email protected]



New Christian Novel Shares Inspirational Story of Love Restored, Forgiveness After Infidelity

In ‘Life with Brody,’ a young, Christian woman feels lost in her marriage and, desperate to learn whether her husband still loves her, creates a dating site profile that tests her faith and takes her on an unexpected journey

WINCHESTER, Idaho, Nov. 30, 2020 (GLOBE NEWSWIRE) — Author K. F. Johnson has published her debut faith-based novel that follows a young woman who feels caught in a loveless marriage, is fearful that her husband is having an affair, and questions her compatibility with him after becoming a Christian.  In “Life with Brody: A findmysoulmate.org Book” protagonist April embarks on an inspirational journey to deepen her understanding of herself, her husband, and their relationship.

After seven years of marriage, it appears that April and Steve’s love has grown cold. Ever since April accepted Christ, their relationship hadn’t been the same. Propelled by a worry that Steve’s affections have drifted elsewhere, April makes a decision that could lead to real trouble and, even worse yet, end her marriage.

To satisfy her curiosity and uncover the truth, April creates a profile on the dating website findmysoulmate.org. Three months earlier, Steve had mentioned the site while contemplating aloud if he and April would still match – especially in the wake of their steadily diverging religious beliefs. But when April receives a message from Bob357, she is driven down an uncertain path where, with help from a rescue dog and God, she discovers the truth about herself and her husband, forever changing the course of their lives and marriage.

“‘Life with Brody’ is a great read to refresh your faith and renew your spirit,” a reader wrote about the book in a five-star review on Amazon. “Life’s struggles are all too real, this book is a great reminder to put our trust in God and give Him control!”

Ultimately, “Life with Brody” is an inspirational story about forgiveness. As Steve teeters on the edge of losing everything, April struggles to stand firm in her marriage and leans on the temptation of companionship with someone else. Throughout the book, April and Steve parse common questions about faith, God, and morality, inviting the reader to relate to each of their perspectives, failures, and victories.

“Life with Brody: A findmysoulmate.org Book”
By K. F. Johnson
ISBN: 978-1-9736-7367-5 (sc)
ISBN: 978-1-9736-7368-2 (hc)
ISBN: 978-1-9736-7366-8 (e)
Available through WestBow Press, Barnes & Noble, and Amazon

About the author
K. F. Johnson was born in Sioux City, Iowa, as the youngest child in a military family. Raised mostly in the U.S., travel and new experiences were common occurrences throughout her childhood. As an adult, her faith and sense of adventure have taken her on many exciting journeys. At age 17, Johnson graduated high school and joined the Army. She settled down in Idaho in her mid-30s, where she met her husband, Greg, who remains a source of love, support, and laughter to this day. Johnson enjoys spending time outdoors, sewing, taking photographs of the mountain scenery around her home, and making specialty birthday cakes, homemade candies, and loaves of bread. She and her husband have rescued two dogs, two cats, and a bird, and they often joke that everyone in their house is a rescue – people included. To learn more, please visit www.findmysoulmate.org.

WestBow Press is a strategic supported self-publishing alliance between HarperCollins Christian Publishing and Author Solutions, LLC — the world leader in supported self-publishing. Titles published through WestBow Press are evaluated for sales potential and considered for publication through Thomas Nelson and Zondervan.  For more information, visit www.westbowpress.com or call (866)-928-1240.

Attachment



Danielle Grobmeier
LAVIDGE
480-648-7557
[email protected]

Clarity Gold to Acquire the Destiny Project Located in the Abitibi Region

VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) — Clarity Gold Corp. (“Clarity” or the “Company”) (CSE: CLAR, OTC: CLGCF, FSE: 27G) is pleased to announce that it has entered into an option agreement (the “Option Agreement”) dated November 27, 2020 pursuant to which the Company has been granted the sole and exclusive option (the “Option”) by Big Ridge Gold Corp. (“Big Ridge”) (TSX-V: BRAU), an arm’s length company whose common shares are listed on the TSX Venture Exchange, to acquire up to 100% of Big Ridge’s right, title and interest in and to certain mineral claims located in the Province of Quebec known as the “Destiny Project” (the “Transaction”).

Highlights of t
he Destiny Project

1

  • Located in the historical, mineral rich Abitibi Greenstone Belt.
  • Gold mineralization occurs in high-grade quartz veins within shear zones starting at 15 m below surface (drill results include 167g/t Au over 1 m).
  • 2011 NI 43-101 indicated resource of 360,000 oz and an inferred resource of 247,000 oz.
  • Mineralization is open to depth and along strike.
  • The DAC deposit is open along strike with only coarse drilling denoting high grade intercepts outside of 2011 resource area showing expansion potential along strike from the DAC Deposit over approximately 2.5 km to the Darla Zone.
  • Excellent infrastructure: ~75 km NNE of Val d’Or with road access.
  • Considerable work done to date including over 50,000 m of diamond drilling.

“This is a substantial step forward for Clarity. The acquisition of the Destiny Project will mark a transformational first step for the Company into the prolific Abitibi Greenstone belt,” stated Clarity’s CEO, James Rogers. “Our team at Clarity has reviewed countless projects and we are excited to focus our efforts on a project that has high grade, underground potential with underpinning Indicated and Inferred ounces in the ground. We look forward to working with Big Ridge to complete the Transaction and get to work on advancing this exciting project.”

___________
1 Information extracted from the Technical Report, dated March 1, 2011, authored by, Todd McCracken, P. Geo., and filed by Big Ridge on SEDAR on March 7, 2011.

The Destiny Project

The Destiny Project is located approximately 75 km northeast of the city of Val d’Or in the prolific Abitibi Greenstone Belt where more than 180 million ounces of gold have been produced historically along major structural breaks within the assemblage of Archean-age volcanic, sedimentary and intrusive rocks. The Destiny Project lies along the approximately 400 km long Chicobi Deformation Zone, a major structural break which is largely underexplored in the Abitibi Greenstone Belt. The 5,013 ha project includes the DAC deposit, one of several gold zones along an approximately 6 km long segment of the Despinassy Shear Zone within the Chicobi Deformation Zone.

Approximately 2.5 km east along strike of the DAC deposit is the Darla zone. In between the Darla and DAC is the coarsely drilled GAP zone where 2012 drilling intercepted anomalous gold in all 12 holes which were spaced 100 m apart.

Exploration of the Destiny Project dates back to the 1930s with the first serious diamond drilling campaign commencing in 1998 by Cameco. Continued exploration and drilling campaigns supported a maiden NI 43-101 resource estimation being authored in 2007 and the most recent NI 43-101 resource estimation in 2011 in the Technical Report, dated March 1, 2011, authored by, Todd McCracken, P. Geo., and filed by Big Ridge on SEDAR on March 7, 2011 (the “2011 Technical Report”). Since the publishing of the 2011 Technical Report, only 15 drill holes totaling approximately 3,473 m were completed as well as geochemical surveys and a geophysical compilation targeting VMS mineralization.

Previous work on the property can be summarized as follows:

  • 172 Diamond drill holes comprising approximately 50,400 m
  • Reconnaissance till sampling from 11 Sonic drill holes
  • 2,430 MMI geochemical samples
  • 982 line km of airborne VTEM surveys
  • 171 line km of ground magnetics surveys
  • 128 line km of IP

Salient results from previous drill programs on the Destiny Project:

Zone Hole ID From (m) To (m) Interval (m) Au g/t
DAC

DES9917 117.2 140.8 23.6 6.15
including 118.8 121.9 3.1 23.95
and 134.8 138.5 3.7 12.46
DES0032 159.9 169.2 9.3 3.98
including 161.2 165.9 4.7 5.37
and 163.3 165.9 2.6 7.78
DES05-64 161.8 170.5 8.7 5.42
including 161.8 163.2 1.4 22.14
DES05-66 130.3 133.1 2.8 5.18
and 138.3 139.3 1.0 3.37
and 142.2 143.6 1.4 8.83
DES05-67 163.7 170.9 7.2 8.81
including 166.0 168.7 2.7 19.49
DES05-79 130.6 133.1 2.5 10.70
and 142.0 145.0 3.0 5.04
DES05-81 323.7 325.8 2.1 3.41
and 333.7 339.0 5.3 4.01
including 333.7 338.5 4.8 4.32
DES06-85 214.0 216.5 2.5 4.31
and 221.7 222.7 1.0 167.00
DES06-96 254.4 261.2 6.8 2.46
and 272.7 275.7 3.0 3.04
DES10-137 372.9 374.0 1.1 25.65
Darla

DES06-91 115.1 117.2 1.2 19.67
DES08-104 104.5 107.0 2.5 6.73
including 104.5 105.2 0.7 19.73
Gap

DES12-147 85.5 91.5 6.0 16.10
including 87.5 88.5 1.0 90.30
and 146.0 148.0 2.0 2.55
West

DES05-75 79.8 80.5 0.7 3.36
and 82.7 84.2 1.5 1.50
and 90.3 91.8 1.5 1.23
South

DES0051 308.6 309.9 1.3 2.22
DES0056 49.0 49.2 0.2 3.03
and 144.6 145.3 0.7 1.69
and 319.0 319.2 0.2 2.23
Zone 21

DES9921 93.8 99.8 6.0 2.49
including 93.8 94.8 1.0 7.03
Zone 20 DES9920 218.4 220.4 2.0 4.60

The DAC Deposit

The 2011 Technical Report entitled “NI 43-101 Technical Report and Resource Estimate of the DAC Deposit, Destiny Property, Quebec” included the following estimates:

Class Tonnes Au
(
gpt
)
Au (ounces)
Indicated 10,800,000 1.05 360,000
Inferred 8,300,000 0.92 247,000

Notes:

  • The 2011 Technical Report was prepared for Alto Ventures Ltd. (now Big Ridge) and Pacific Northwest Capital Corp.
  • Values rounded to reflect summary nature of the estimate
  • Cut-off grade 0.5 g/t Au
  • Au price of US$973/Oz
  • US$ to CAD$ conversion of 1.02
  • Au recovery 94%
  • 4:1 Strip ratio
  • Operating cost of $14.30/t at 10,000 tpd

Michel Robert, Advisor to Clarity stated: “The Abitibi is known for its high mineral potential, it’s a recognized region in Canada and internationally. I have previously worked in several active projects in the region, now I am excited to return to this highly prospective area with solid infrastructure and formidable local support for resource development. Destiny is in an advanced exploratory stage with an NI 43-101 indicated resource, and with multiple underexplored zones which makes for untapped exploration potential. At Clarity, we look forward to starting work and further defining this resource to become another success in the region.”

About the Option Agreement

Under the Option Agreement, Big Ridge has granted the Option to the Company which may be exercised by the Company on or prior to the third anniversary of the closing of the Transaction (the “Closing”) by making the following cash payments and issuances of common shares of the Company (each, a “Clarity Share”) on or before the dates indicated below:

Payment Date Cash Payment Amount Share Issuance $ Amount Interest Earned
Previously paid on execution of the letter of intent between the parties dated October 29, 2020 $50,000
Within 60 days of the execution of the Option Agreement $450,000 $1,000,000
12 months from the date of the Option Agreement $750,000 $1,000,000
24 months from the date of the Option Agreement $750,000 $1,500,000 49% earned
36 months from the date of the Option Agreement $1,000,000 $2,000,000 100% earned
Total: $3,000,000 $5,500,000  

The Company may accelerate the exercise of the Option by making the cash payments and issuances of Clarity Shares earlier than the timeframes contemplated above. The number of Clarity Shares to be issued to Big Ridge pursuant to the Option will be determined by dividing the dollar amount of Clarity Shares to be issued at any point in time by the five (5) day volume weighted average closing price of the Clarity Shares on the day before such issuance of such Clarity Shares, subject to the policies of the CSE. Concurrently with the exercise of the Option, Clarity has agreed to grant to Big Ridge a 1.0% net smelter return royalty (the “Royalty”) with respect to production of all precious metals from the Destiny Project, with the Royalty to be payable by Clarity following commencement of commercial production. The Company has the right to buy back the Royalty during the first three (3) years following the commencement of commercial production on payment by Clarity to Big Ridge of $1,000,000. Exercise of the Option is subject to receipt of all applicable regulatory approvals and consents. The Company will be the operator responsible for carrying out all operations with respect to the Destiny Project during the term of the Option Agreement. If Clarity acquires a 49% interest in the Property and decides not to proceed with the acquisition of the further 51% interest in the Property, then, for a period of 18 months following such time, Big Ridge will have the right to purchase back the 49% interest in the Property for cash consideration of $2,000,000. Clarity has agreed to pay a finders’ fee equal to 3% of the aggregate consideration payable to Big Ridge. Closing of the transactions contemplated under the Option Agreement is subject to the typical customary conditions, including receipt of all regulatory approvals.

Private Placement

The Company also announces a non-brokered private placement financing (the “Offering”) of units of the Company (each, a “Unit”) at a price of $0.96 per Unit. The Company intends to issue 3,125,000 Units for gross proceeds of $3,000,000 but may issue up to 10,000,000 Units of the Company for gross proceeds of up to $9,600,000. Each Unit will consist of one common share (each, a “Share”) and one-half of one transferable warrant (each whole warrant, a “Warrant”), with each Warrant entitling the holder thereof to purchase one additional Share at a price of $1.25 per Share for a period of one year from closing of the Offering.

Completion of the Offering is subject to a number of conditions, including, without limitation, receipt of all necessary regulatory approvals. Insiders of the Company may participate in the Offering and finders’ fees may be paid in connection with the Offering. The net proceeds of the Offering will be used for the required payments and exploration expenditures in connection with the Option with respect to the Destiny Project, for exploration to advance the understanding of the Company’s other mineral exploration properties, marketing, costs of operations and general working capital.

All securities issued in connection with the Transaction and the Offering will be subject to a hold period of four months and one day from the date of issuance in accordance with applicable securities legislation.

None of the securities issued in the Transaction and the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

Qualified Person

Mr. Rory Kutluoglu P. Geo. is the Qualified Person (“QP”) under NI 43-101 for the technical information in this news release and has reviewed the appropriate and available data for the Destiny Project and approves the technical contents of this news release.

About Clarity

Clarity Gold Corp. is a Canadian mineral exploration company focused on the acquisition, exploration and development of gold projects in Canada. The Company has entered into an option agreement to purchase 100% of the Destiny Project, a 5,013 ha gold-focused project in the mineral rich Abitibi region in Quebec. Clarity is also working on the exploration of its 10,518 ha Empirical Project located approximately 12 km south of Lillooet, BC, and has recently expanded its mineral property portfolio with the acquisitions of the Tyber and Gretna Green projects, both located on Vancouver Island, British Columbia. The Company is based in Vancouver, British Columbia, and is listed on the CSE under the symbol “CLAR”. To learn more about Clarity Gold Corp. and its projects please visit www.claritygoldcorp.com.

ON BEHALF OF THE BOARD

James Rogers
Chief Executive Officer
Tel: 1 (833) 387-7436
Email: [email protected] 
Website: www.claritygoldcorp.com 

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements regarding
: the Transaction and the terms thereof;
that the acquisition of the Destiny Project will mark a transformational first step for the Company into the Abitibi Greenstone belt
;
that the Company will exercise the Option;
that the Company will complete the Offering; and
the intended use of the proceeds
of the Offering
. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements
including:
that the
Company
may not be able to satisfy the conditions to
exercise the Option;
the inability of the Company to complete the Offering at all or on the terms announced
;
adverse market conditions; and other factors beyond the control of the parties
.
Although the Company believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not
guarantees
of future performance and, accordingly, undue reliance should not be put on such statements due to their inherent uncertainty. Factors that could cause actual results or events to differ materially from current expectations include general market conditions and other factors beyond the control of the Company. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.



Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx Conference

WALTHAM, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 2020 Evercore ISI HealthCONx Conference on Thursday, December 3, 2020 at 1:25 p.m. ET. The conference will be held in a virtual meeting format.

Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a fireside chat. The event will be available live via webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website at https://investors.apellis.com/events-and-presentations. A replay of the webcast will be available for 90 days following the event.

About Apellis

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

Investor Contact:

Argot Partners
[email protected]
+1 212.600.1902



Corsair Gaming Updates Full Year 2020 Outlook

Net Revenue, Adjusted Operating Income and Adjusted EBITDA Expected to Exceed Prior Guidance

FREMONT, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) — Corsair Gaming, Inc. (NASDAQ:CRSR) (“Corsair”), a leading global provider and innovator of high-performance gear for gamers and content creators, today announced it expects full year 2020 net revenue, adjusted operating income and adjusted EBITDA to exceed the expectations Corsair provided on November 10, 2020.

“The positive momentum in our business continues to exceed our expectations in both of our business segments. In our Gaming and Creator segment, we continue to see strong sales in all price points, which we believe indicates that we have both new customers buying gear as well as existing customers refreshing and upgrading. The highest growth continues to be in our streaming products, as gamers want to share video content with their friends and fans. In our Components and Systems segment, we are also seeing continued enthusiasm to build new high end gaming PCs based on recently introduced high performance CPUs and GPUs. We are excited to see that more and more people are using our RGB components and accessories powered by our iCue software in these builds,” commented Andy Paul, Chief Executive Officer of Corsair. “Our recent announcements of our acquisition of Gamer Sensei and our partnership with Pipeline underscore our initiatives to build a meaningful coaching and training business inside Corsair. We believe this will further enhance our engagement level with gamers and content creators.”

Andy Paul continued, “For the full year 2020, which ends December 31, we now expect net revenue growth of approximately 50% to 52% and adjusted operating income growth of approximately 183% to 192%. We will provide more details when we report our fourth quarter results and provide full year 2021 guidance in February.”

Corsair is providing this update in advance of Corsair management participating in the Credit Suisse Technology Conference on Monday, November 30, 2020, and the Barclays Global Technology, Media and Telecommunications Virtual Conference on December 9, 2020. Interested parties can listen to a live webcast,  as well as a replay,  of Corsair’s investor relations website at https://ir.corsair.com.

Financial Outlook

For the full year 2020, we currently expect:

  • Net revenue to be in the range of $1,651 million to $1,666 million.
  • Adjusted operating income to be in the range of $186 million to $192 million.
  • Adjusted EBITDA to be in the range of $194 million to $200 million.

Certain non-GAAP measures included in our financial outlook were not reconciled to the comparable GAAP financial measures because the GAAP measures are not accessible on a forward-looking basis. We are unable to reconcile these forward looking non-GAAP financial measures to the most directly comparable GAAP measures without unreasonable efforts because we are currently unable to predict with a reasonable degree of certainty the type and extent of certain items that would be expected to impact GAAP measures for these periods but would not impact the non-GAAP measures. Such items may include stock-based compensation charges, public offering related charges, depreciation and amortization, severance, IPO costs and other items. The unavailable information could have a significant impact on our GAAP financial results.

The foregoing forward-looking statements reflect our expectations as of today’s date. Given the number of risk factors, uncertainties and assumptions discussed below, actual results may differ materially. We do not intend to update our financial outlook until our next quarterly results announcement.

Please see “Use of Non-GAAP Financial Measures” below for a discussion on how we calculate the non-GAAP measures presented herein.

About Corsair Gaming, Inc.

Corsair Gaming, Inc. (NASDAQ:CRSR) is a leading global developer and manufacturer of high-performance gear and technology for gamers, content creators, and PC enthusiasts. From award-winning PC components and peripherals, to premium streaming equipment and smart ambient lighting, Corsair delivers a full ecosystem of products that work together to enable everyone, from casual gamers to committed professionals, to perform at their very best.

Corsair also sells gear under our Elgato brand, which provides premium studio equipment and accessories for content creators, SCUF Gaming brand, which builds custom-designed controllers for competitive gamers, and ORIGIN PC brand, a builder of custom gaming and workstation desktop PCs and laptops.

Forward Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, our estimated full year 2020 net revenue, adjusted EBITDA and adjusted operating income, as well as our belief that more new gamers and streamers are entering the market, that there is an increased demand for people to build new gaming PCs and our expectations regarding the capacity of our supply chain and manufacturing capabilities and our potential growth of channel inventory to meet customer demand. Forward-looking statements are based on our management’s beliefs, as well as assumptions made by, and information currently available to, them. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. Factors which may cause actual results to differ materially from current expectations include, but are not limited to: the impact of COVID-19 on the ability of retail stores to be open and one our supply chain, our ability to build and maintain the strength of our brand among gaming and streaming enthusiasts and our ability to continuously develop and successfully market new gear and improvements; the introduction and success of new third-party high-performance computer hardware, particularly graphics processing units and central processing units as well as sophisticated new video games; the risk that we are not able to compete with competitors and/or that the gaming industry, including streaming and eSports, does not grow as expected or declines; the loss or inability to attract and retain key management; delays or disruptions at our or third-party’s manufacturing and distribution facilities; currency exchange rate fluctuations or international trade disputes resulting in our gear becoming relatively more expensive to our overseas customers or resulting in an increase in our manufacturing costs; the impact of the coronavirus on our business; general economic conditions that adversely effect, among other things, consumer confidence and spending; and the other factors described under the heading “Risk Factors” in our final prospectus filed with the Securities and Exchange Commission (“SEC”) on September 24, 2020, in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and our subsequent filings with the SEC. Copies of each filing may be obtained from us or the SEC. All forward-looking statements reflect our beliefs and assumptions only as of the date of this press release. We undertake no obligation to update forward-looking statements to reflect future events or circumstances. Our results for the quarter ended September 30, 2020 are not necessarily indicative of our operating results for any future periods.

Use of Non-GAAP Financial Measures

To supplement the financial results presented in accordance with GAAP, this earnings release presents certain non-GAAP financial information, including adjusted operating income and adjusted EBITDA. These are important financial performance measures for us, but are not financial measures as defined by GAAP. The presentation of this non-GAAP financial information is not intended to be considered in isolation of or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We use adjusted operating income and adjusted EBITDA to evaluate our operating performance and trends and make planning decisions. We believe that these non-GAAP measures help identify underlying trends in our business that could otherwise be masked by the effect of the expenses and other items that we exclude in such non-GAAP measures. Accordingly, we believe that adjusted operating income and EBITDA margin provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to the key financial metrics used by our management in our financial and operational decision-making. We also present these non-GAAP financial performance measures because we believe investors, analysts and rating agencies consider them useful in measuring our ability to meet our debt service obligations.

Our use of these terms may vary from that of others in our industry. These non-GAAP financial measures should not be considered as an alternative to revenues, operating income, net income, cash provided by operating activities or any other measures derived in accordance with GAAP as measures of operating performance or liquidity. Reconciliations of these measures to the most directly comparable GAAP financial measures are presented in the attached schedules.

We calculate these non-GAAP financial measures as follows:

  • Adjusted operating income, non-GAAP, is determined by adding back to GAAP operating income the acquisition accounting impacts related to recognizing acquired inventory at fair value, stock-based compensation, intangible asset amortization, certain acquisition-related and integration-related expenses, executive transition costs, other non-deferred costs associated with the IPO, and debt modification costs.
  • Adjusted EBITDA is determined by adding back to GAAP net income (loss) the acquisition accounting impacts related to recognizing acquired inventory at fair value, stock-based compensation, certain acquisition-related and integration-related expenses, executive transition costs, non-deferred costs associated with the IPO, debt modification costs, intangible asset amortization, depreciation and amortization, interest expense (including loss on extinguishment of debt) and tax expense (benefit).

We encourage investors and others to review our financial information in its entirety, not to rely on any single financial measure and to view these non-GAAP financial measures in conjunction with the related GAAP financial measures.

Source: Corsair Gaming, Inc.

Investor Relations Contact:

Ronald van Veen
[email protected]
510-578-1407

Media Contact:

Adrian Bedggood
[email protected]
510-657-8747
+44-7989-258827